Broyer M
Département de pédiatrie médicale, Néphrologie pédiatrique, Groupe hospitalier Necker-Enfants malades, Paris.
Rev Prat. 1997 Sep 15;47(14):1550-3.
Infantile cystinosis is a metabolic lysosomal storage disease of cystine affecting most of the body cells. The first symptoms appear after 5-6 months of life: anorexia, vomiting, polyuria, polydipsia and failure to thrive, associated with the signs of tubular Fanconi syndrome including glycosuria, proteinuria, loss of bicarbonate, phosphate, potassium, sodium, etc. Treatment with cysteamine is effective if started as early as possible. This treatment delays or prevents the spontaneous evolution toward end-stage renal failure, usually between 6 and 12 years of age, and also prevents growth stunting. In the long term, other organs may be involved like eye, thyroid, endocrine pancreas, muscle and central nervous system. The diagnosis is ascertained by leucocytes cystine assay, also useful for the follow up and the adjustment of the treatment. Prenatal diagnosis is available on chorionic sample. The gene of the disease is not yet identified but is known to map to chromosome 17.
婴儿胱氨酸病是一种影响身体大多数细胞的胱氨酸代谢性溶酶体贮积病。最初症状在出生后5至6个月出现:厌食、呕吐、多尿、多饮和发育不良,伴有肾小管范科尼综合征的体征,包括糖尿、蛋白尿、碳酸氢盐、磷酸盐、钾、钠等流失。如果尽早开始使用半胱胺治疗是有效的。这种治疗可延迟或防止通常在6至12岁时向终末期肾衰竭的自然发展,还可防止生长发育迟缓。从长远来看,其他器官可能会受累,如眼睛、甲状腺、内分泌胰腺、肌肉和中枢神经系统。通过白细胞胱氨酸检测来确诊,这对随访和治疗调整也很有用。可对绒毛样本进行产前诊断。该疾病的基因尚未确定,但已知定位于17号染色体。